Pacira BioSciences (NasdaqGS:PCRX) FY Conference December 02, 2025 01:30 PM ET Company ParticipantsShawn Cross - CFOConference Call ParticipantsBiren Amin - Senior Research AnalystBiren AminYou're welcome, everyone, to the Piper Sandler Healthcare Conference. My name is Biren Amin. I'd like to welcome our next company. We have Pacira BioSciences and their Chief Financial Officer, Shawn. Welcome, Shawn, to our conference, and thanks for attending. Maybe, you know, start off, provide a brief overview. You kno ...

LivaNova (NasdaqGS:LIVN) FY Conference December 02, 2025 01:30 PM ET Company ParticipantsPhil Kowalczyk - Chief Strategy and Corporate Development OfficerAlex Shvartsburg - CFOModeratorAll right, perfect. We're going to get going here. Welcome to the 2025 Piper Sandler Healthcare Conference. My name is Adam Maeder. I think we're live. Okay, clock's not running, but, but we are live. I'm one of the analysts here at Piper Sandler. Introducing the management team from LivaNova. With us, we have Alex Shvartsbur ...

Monte Rosa Therapeutic (NasdaqGS:GLUE) FY Conference December 02, 2025 01:30 PM ET Company ParticipantsMarkus Warmuth - CEOConference Call ParticipantsTed Tenthoff - Senior Biotech AnalystTed TenthoffGreat. Good afternoon, everyone. My name is Ted Tenthoff. I'm a senior biotech analyst at Piper Sandler. And before I begin, I'm required to point out certain disclosures regarding the relationship between our next presenting company, Monte Rosa, and Piper, which are listed at the back of the room and also at t ...

AnaptysBio (NasdaqGS:ANAB) FY Conference December 02, 2025 01:30 PM ET Company ParticipantsDaniel Faga - President and CEOConference Call ParticipantsYas Rahimi - Senior Biotech AnalystYas RahimiGood afternoon, everyone. Welcome to our Piper Sandler Healthcare Conference. My name is Yas Rahimi. I'm a Senior Biotech Analyst here at Piper Sandler, and the covering analyst of AnaptysBio. Dan, it's wonderful to have you. We have lots to cover over the next 25 minutes, and you have a packed schedule, so you've b ...

Butterfly Network (NYSE:BFLY) FY Conference Summary Company Overview - Butterfly Network specializes in medical imaging, particularly handheld ultrasound devices, aiming to democratize access to imaging technology globally [4][10] - The company has developed an innovative ultrasound-on-a-chip technology, allowing for a single device to perform multiple imaging functions, unlike traditional ultrasound machines that require multiple devices for different body parts [8][10] Market Dynamics - The global ultrasound market is valued at approximately $10 billion, with the handheld ultrasound segment estimated at $300-$400 million [20][27] - Currently, handheld devices represent about 40%-50% market share in unit volume, while revenue share is lower due to lower pricing compared to traditional machines [27] - The company aims to position its device as the "stethoscope of the future," promoting widespread adoption among doctors and nurses [13][14] Competitive Landscape - Butterfly Network is competing against established players like GE, with a focus on both traditional ultrasound markets and other handheld devices [27] - The company claims to have a significant market share in developed markets, particularly in medical schools, where it is present in about 70% of institutions [30] Adoption and Innovation - The adoption of handheld ultrasound devices is expected to grow as AI technology improves, making it easier for non-specialists to use ultrasound effectively [15][24] - Butterfly Network is on its third-generation chip, with plans for a fourth-generation chip by late 2026, enhancing image quality and functionality [24] Financial Performance and Projections - The company ended Q3 with $148 million in cash and expects to reduce cash usage from $45 million last year to approximately $40 million this year [33] - Adjusted EBITDA loss is projected to be between $32 million and $35 million, indicating improved financial management [33] - Butterfly Network has set a long-term revenue target of $500 million by 2028, supported by both organic growth and new business opportunities, including partnerships for licensing its semiconductor technology [34][35] Challenges and Future Outlook - The company has faced challenges in hospital sales due to budget constraints and changes in global health funding, but anticipates a recovery in 2026 [31] - The focus on private donors and expanding its market presence in developing countries is seen as crucial for future growth [31] Key Takeaways - Butterfly Network is positioned to disrupt the traditional ultrasound market with its innovative technology and business model, aiming for widespread adoption among healthcare professionals [10][14] - The integration of AI and continuous innovation in imaging technology are critical to overcoming barriers to adoption and enhancing the device's capabilities [15][24] - Financial stability and strategic partnerships will play a significant role in achieving the company's ambitious revenue goals [34][35]

Vaxcyte (NasdaqGS:PCVX) FY Conference December 02, 2025 01:20 PM ET Company ParticipantsJames Wassil - COOAndrew Guggenhime - President and CFOModeratorSo, Andrew, I woke up Saturday and I had a text message from Vinay. I'm like, Vinay's texting me. What is going on? And I realized I was on some email chain. So I started reading it, and that's when I shot you an email on Saturday morning. Wow, what's going on here? So let's just start. Where are things standing on FDA? Because I feel like that's probably th ...

Halozyme Therapeutics (NasdaqGS:HALO) FY Conference December 02, 2025 01:20 PM ET Company ParticipantsHelen Torley - President and CEOConference Call ParticipantsMichael DiFiore - Senior Biotech AnalystMichael DiFioreOkay, let's get started. Welcome, everybody. Welcome to our conference in Miami. I have the pleasure of having Dr. Helen Torley, CEO of Halozyme Therapeutics. Helen, welcome. Thanks so much for making time for us. Before we delve into Q&A, I'd love to get your overview of the business and maybe ...

Regeneron Pharmaceuticals FY Conference Summary Company Overview - **Company**: Regeneron Pharmaceuticals (NasdaqGS:REGN) - **Date of Conference**: December 02, 2025 Key Accomplishments in 2025 - **Eylea HD**: Significant growth noted, with recent label enhancements for Q4 weekly dosing and RVO indication expected to drive future uptake. The RVO indication represents about 20% of the overall market and 17-18% of Eylea's business [6][7][17] - **Dupixent**: Expanded to eight indications in the U.S., with strong international performance. Recent approvals include COPD, bullous pemphigoid, and CSU, with a total potential patient population of approximately 927,000 [7][11][39] - **Libtayo**: Successful label expansion for adjuvant CSCC, with positive reception from the KOL community. The launch is progressing well, with a focus on early treatment paradigms [8][50] - **Linvoseltamab**: Launched for advanced treatment indications, showing early interest and uptake in the community [9][53] - **Ultra-Rare Disease Portfolio**: Continued advancements in the ultra-rare disease space, including Evkeeza for HoFH [10] Pipeline and Future Developments - **Immunology**: Positive data for Dupixent in allergic fungal rhinosinusitis, with a PDUFA date in February. Ongoing expansion in various indications [11][12] - **Neurology**: Cemdisiran for generalized myasthenia gravis shows potential in a $5 billion market, expected to double by 2030 [67][68] - **Oncology**: Libtayo's adjuvant CSCC indication is expected to have a gradual uptake, with significant investment in marketing to relevant medical professionals [50][51] - **Ophthalmology**: Eylea HD is positioned strongly against competitors, with ongoing development of new therapies targeting glaucoma and other conditions [35][36] Financial Highlights - **Capital Allocation**: Initiated a dividend with a modest yield, returning approximately $4 billion through dividends and share repurchases in 2025. Increased share repurchase from $2.6 billion in 2024 to an anticipated $3.6 billion in 2025 [13][14] - **Investment in U.S. Manufacturing**: Committed over $7 billion to enhance manufacturing and research capabilities in the U.S. [14] Market Dynamics and Competitive Landscape - **Biosimilars Impact**: Eylea's business has shifted towards Eylea HD, with some episodic uptake of biosimilars. The market is complicated by affordability issues, impacting brand selection [26][28] - **Next-Gen Products**: Regeneron is monitoring competition from bispecifics and multispecifics but remains confident in Eylea HD's competitive profile [30][34] Lifecycle Management and Future Strategies - **Dupixent Lifecycle Management**: Exploring ways to extend dosing intervals and develop adjacent pathways, with a broad pipeline of over 45 clinical candidates [44][46] - **Business Development**: Active in seeking collaborations and partnerships, including a recent $150 million deal with Tessera for gene editing opportunities [75] Conclusion - Regeneron Pharmaceuticals has had a productive year in 2025, with significant advancements in product performance, pipeline development, and capital allocation. The company is well-positioned for continued growth in 2026, focusing on optimizing existing products and advancing innovative therapies across various therapeutic areas [78][80]

Summary of Castle Biosciences FY Conference Call Company Overview - Castle Biosciences is a molecular diagnostics company focused on proprietary algorithm-driven tests aimed at improving patient management and outcomes [2][3] Industry and Market Insights - The company operates primarily in the dermatology and gastroenterology sectors, with tests designed for conditions such as melanoma, atopic dermatitis, and Barrett's esophagus [5][7] - The total addressable market (TAM) for their tests is significant, with estimates of $540 million for melanoma tests, $820 million for high-risk cutaneous squamous cell carcinoma, and $1 billion for Barrett's esophagus [9][10][11] Financial Performance - In Q3 2025, Castle Biosciences reported a revenue growth of 36% year-over-year, matching the volume growth [2] - Adjusted gross margins decreased to 77% from 82% due to the loss of coverage for squamous cell carcinoma tests [3] - The company ended the quarter with cash and cash equivalents of $287 million, indicating a strong balance sheet [3] Product Developments - The company launched a new test called Advance ADTX for guiding systemic therapy selection in patients with moderate to severe atopic dermatitis [4] - The DecisionDx-SCC test demonstrated the ability to predict the likelihood of response to adjuvant radiation therapy in high-risk cutaneous squamous cell carcinoma patients [6] - Ongoing collaboration with SciBase aims to predict flares in atopic dermatitis patients using electrical impedance spectroscopy technology [7] Clinical Study Findings - A large prospective observational study validated a 487 gene expression profile test for atopic dermatitis, identifying two key profiles: TH2 molecular profile and JAK inhibitor responder profile [12][19] - Patients with a JAK inhibitor responder profile had a 45% chance of achieving EASI-90 (90% clearance) when treated with JAK inhibitors, compared to only 8.3% with TH2 biologic therapy [19] Market Research and Adoption - Approximately 78% of clinicians surveyed indicated they would likely use the new atopic dermatitis test after a brief overview [20] - The target population for the atopic dermatitis test is around 13 million patients aged 12 and older in the U.S. [10][22] Conclusion - Castle Biosciences is positioned for growth with a strong product pipeline and significant market opportunities in dermatology and gastroenterology, supported by promising clinical data and positive clinician feedback [23]

Perspective Therapeutics (NYSEAM:CATX) FY Conference December 02, 2025 01:00 PM ET Company ParticipantsThijs Spoor - CEOConference Call ParticipantsBiren Amin - Managing Director and Senior Research AnalystBiren AminTo the Piper Sandler Healthcare Conference, my name is Biren Amin. I'd like to introduce our next company. We have Perspective Therapeutics and their CEO, Thijs Spoor. Thanks, Thijs, for coming and attending and sharing their Perspective story. So maybe you could tell us about you are clearly fo ...